Relebactam Anhydrous

Summary

Relebactam Anhydrous (CHEMBL3112741) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Clinical trials: 1
• Chemistry: 348.38 Da · C12H20N4O6S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3112741
Name	Relebactam Anhydrous
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	44129647
Molecular formula	C12H20N4O6S
Molecular weight	348.38
InChIKey	SMOBCLHAZXOKDQ-ZJUUUORDSA-N

SMILES: C1C[C@H](N2C[C@@H]1N(C2=O)OS(=O)(=O)O)C(=O)NC3CCNCC3

IUPAC name: [(2S,5R)-7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate

Also known as: (-)-relebactam anhydrous, Mk-7655, Relebactam anhydrous

Parent form; salt/anhydrous children: CHEMBL3301605, CHEMBL4516632

Patent coverage: 195 distinct patent families (408 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01275170	PHASE1	COMPLETED	A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).